Skip to content

A controlled study on the improvement of negative symptoms of schizophrenia by accurate iTBS based on brainnetome

A controlled study on the improvement of negative symptoms of schizophrenia by accurate iTBS based on brainnetome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071407
Enrollment
Unknown
Registered
2023-05-15
Start date
2023-05-15
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

one:active iTBS
Two:sham iTBS

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Meets DSM-5 diagnostic criteria for schizophrenia. (2) Age 18-50, either gender, right-handed, with at least 8 years of education. (3) Negative symptoms scale of PANSS score >= 21, with a score of >= 4 on any one item from N1 to N7. (4) Within the 2 weeks prior to intervention, a reduction of <10% in the PANSS negative symptom scale score. (5) The antipsychotic medication regimen (type and dosage) should remain unchanged for at least 4 weeks prior to study inclusion. (6) The Positive and Negative Syndrome Scale (PANSS) positive symptom scale score is <20, with a score of <4 on each of the items P1-P4. (7) The antipsychotic medication regimen (type and dosage) should remain unchanged until the end of the study. (8) Calgary Depression Scale for Schizophrenia (CDSS) score <6. (9) Signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Contraindication to rTMS, such as the presence of metal objects near the scalp, including intracranial metal implants, cochlear implants, and implanted pulse generators (e.g., deep brain stimulators or cardiac pacemakers). (2) IQ 2mg/day, diazepam > 10mg/day). (8) Clear history of epilepsy or previous seizures. (9) Received stimulants (e.g., methylphenidate, modafinil, or amphetamines), electroconvulsive therapy, rTMS, or other non-invasive brain stimulation treatments within the past 6 months. (10) Inability or unwillingness to cooperate with effective assessment and treatment.

Design outcomes

Primary

MeasureTime frame
PANSS negative symptom subscale;the score of SANS;

Secondary

MeasureTime frame
the score of CAINS;PANSS positive symptom subscale;CGI;PANSS general symptom subscale;The score of CDSS;the score of PSP;the score of MCCB;fMRI;

Countries

China

Contacts

Public ContactChuanyue Wang

Beijing Anding Hospital Affiliated to Capital Medical University

wang_cy@ccmu.edu.cn+86 10 5830 3195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026